XG005 for Pain Control in Subjects Undergoing Bunionectomy
Acute Pain
About this trial
This is an interventional prevention trial for Acute Pain
Eligibility Criteria
Main inclusion criteria: Scheduled to undergo unilateral first metatarsal bunionectomy Have negative urine drug screen Non-pregnant, non-lactating Main exclusion criteria: Medical condition or history that in the investigator's opinion could adversely impact the subject's participation or safety Use of disallowed medications (e.g. pain medication, CNS active drugs such as benzodiazepines, tricyclic antidepressants, Serotonin, and norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), or any other serotonergic medications, parenteral or oral corticosteroids) Antihypertensive agent or diabetic regimen at a dose that has not been stable for at least 30 days Digoxin, warfarin lithium, theophylline preparations, aminoglycosides, and all antiarrhythmics Monoamine oxidase inhibitors (MAOIs) Positive HbsAg and/or anti-HBc but negative anti-HBs HIV infection History of illicit drug use History of opioid dependence History of NSAID-induced bronchospasm or presence of nasal polyps, history of asthma or chronic rhinitis Significant history of allergic reactions or known intolerance to naproxen, pregabalin or any gabapentinoid, or to any rescue medication used in the study, or any medication used in the surgical and anesthetic protocol. Presence of severe depression as indicated by Patient Health Questionnaire (PHQ 9) total score of ≥20 or item 9 score >0 Presence of severe anxiety as indicated by General Anxiety Disorder (GAD-7) score of ≥15 Presence of history of suicidal behavior or ideation as indicated by the C-SSRS
Sites / Locations
- Midwest Clinical Research CenterRecruiting
- First Surgical HospitalRecruiting
- Legent Orthopedic Hospital
- Memorial Hermann Village
- Endeavor Clinical TrialsRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
high dose
low dose
placebo
XG005 1250 mg Q12 hours
XG005 750 mg Q12 hours
placebo Q12 hours